Upon the patient’s initial presentation with high-risk prostate cancer, a staging prostate-specific membrane antigen (PSMA) piflufolastat F 18 (Pylarify; Billerica, MA: Lantheus) scan was obtained [7,8]. This evidence concerns the gene FOLH1 and Familial prostate cancer.